zurück

EU-HTA

#

Does the Joint Clinical Assessment (JCA) hold a hidden lever for orphan drug pricing in Germany?

03.09.2026
In the German AMNOG process, the G-BA does not define an appropriate comparative therapy (ACT) for orphan drugs...
#

Fallacy 11: The Health Technology Developers fact check is only about correcting factual errors. Really?

01.09.2026
The factual accuracy check is formally intended to identify errors in the JCA report...
#

The new EU HTA reality: first insights from JCA and G-BA

20.08.2026
The tovorafenib (Ojemda®, Ipsen) procedure in pediatric low-grade glioma therefore provides the first real-world case of how the JCA and a subsequent national HTA assessment interact ...
#

Fallacy 10: Clinical expert input has little influence on the JCA scope.

19.08.2026
The role of patients, caregivers and clinical experts in the JCA process may appear limited so far.
#

EMA announces Phased Review for daraxonrasib

18.08.2026
On 7 July 2026, the EMA announced a Phased Review for daraxonrasib (Revolution Medicines) for the treatment of metastatic pancreatic adenocarcinoma.
#

JCA Update August 2026

14.08.2026
We’ve analyzed actual JCA procedures resulting from the Committee for Medical Products for Human Use (CHMP).
#

German HTA insights from April to June 2026

06.08.2026
Last week, we’ve announced the release of our analysis of HTA decisions across 10 countries ...
#

PART 19: EU Joint Scientific Consultation (JSC)

04.08.2026
Are you ready for the next request window?
#

Access Briefing Q2 2026

31.07.2026
Our HTA insights Q2 2026 are now available ...
#

PART 18: Assessment Scope Explanation Meeting – helpful milestone or limited dialogue?

23.07.2026
How valuable is the Assessment Scope Explanation Meeting within the JCA framework?
#

Fallacy 9: EU HTA can simply be managed alongside existing responsibilities

09.07.2026
One of the most common assumptions we hear is that EU HTA can be absorbed into existing Market Access or HEOR activities ...
#

Tool News 17: JCA scoping process, predictability and transparency

08.07.2026
How predictable is the PICO scoping process within the JCA framework?

 

Ansprechpartner

Janine Leismann

Janine Leismann
Tel.: +49 (40) 41 33 081-26
j.leismann(at)ecker-ecker.de